Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ACAT1 | P24752 | 1/20 | 0.48 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332741 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL16386595 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL16386591 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL5703634 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL28916787 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL6921290 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL3731170 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL2182268 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL6879505 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 | |
| SCHEMBL11668066 | 1.00 | CYP4F2 (0.52) | CYP4F2CYP4A11MAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0362459-B1 | Polyacrylate polymers utilizing substituted urea retarder | ZEON CHEMICALS USA INC (US) | 1994-08-10 | — | — | EP | claimed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-7994152-B2 | Method of treating a cancer by administering A 2′,5′-oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | SANKYO COMPANY, LIMITED (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7651999-B2 | phosphorothioate modification containg oligonadenylates useful as antiviral, anticarcinogenic and antitumor agent; stable and have superior activity for treating lung cancer | SANKYO COMPANY, LIMITED (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-0930065-B1 | Alcohol based anti-microbial compositions with cosmetic appearance | ETHICON INC (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-0948312-B1 | AQUEOUS COSMETIC COMPOSITIONS WITH BASE OF NON-VOLATILE INSOLUBLE SILICONS, STABILISED BY A SUCCINOGLYCAN | RHODIA CHIMIE SA (FR) | 2004-04-21 | — | — | EP | disclosed |
| US-6300296-B1 | LIQUID DETERGENT FOR DISHES OR TEXTILES WITH FOAMING AGENTS FOR GREASE | RHODIA CHIMIE (FR) | 2001-10-09 | — | — | US | disclosed |
| EP-1043972-A1 | USE OF SILICONES WITH ESTER FUNCTIONS AS ANTI-TRANSFER AGENTS IN COSMETIC COMPOSITIONS | RHODIA CHIMIE (FR) | 2000-10-18 | — | — | EP | disclosed |
| EP-0963430-A1 | FOAMING AQUEOUS MEDIUM STABLE IN THE PRESENCE OF GREASE, STABILISATION OF A FOAMING AQUEOUS MEDIUM IN THE PRESENCE OF GREASE | RHODIA CHIMIE (FR) | 1999-12-15 | — | — | EP | disclosed |
| US-5997893-A | ALCOHOL, AN EFFECTIVE AMOUNT OF A CATIONIC ANTIMICROBIAL COMPOUND, AND A CARBOMER | ETHICON, INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0948312-A1 | AQUEOUS COSMETIC COMPOSITIONS WITH BASE OF NON-VOLATILE INSOLUBLE SILICON, STABILISED BY A SUCCINOGLYCAN | RHODIA CHIMIE (FR) | 1999-10-13 | — | — | EP | disclosed |
| EP-0930065-A2 | Alcohol based anti-microbial compositions with cosmetic appearance | ETHICON, INC. (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1999034775-A1 | USE OF SILICONES WITH ESTER FUNCTIONS AS ANTI-TRANSFER AGENTS IN COSMETIC COMPOSITIONS | RHODIA CHIMIE (FR) | 1999-07-15 | — | — | WO | disclosed |
| WO-1998033877-A1 | FOAMING AQUEOUS MEDIUM STABLE IN THE PRESENCE OF GREASE, STABILISATION OF A FOAMING AQUEOUS MEDIUM IN THE PRESENCE OF GREASE | RHODIA CHIMIE (FR) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998024408-A1 | AQUEOUS COSMETIC COMPOSITIONS WITH BASE OF NON-VOLATILE INSOLUBLE SILICON, STABILISED BY A SUCCINOGLYCAN | RHODIA CHIMIE (FR) | 1998-06-11 | — | — | WO | disclosed |
| EP-0351428-A1 | COMPOSITIONS AND LUBRICANTS AND FUNCTIONAL FLUIDS CONTAINING SAME | The Lubrizol Corporation (US) | 1990-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035976-A1 | Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog | ADAR, NSUN2, ADORA3 | CYP4F2 4294/4885CYP4A11 2841/4885MAPT 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.